💊TEIJIN | News | Teijin Signs Exclusive License and Co-Development Agreement for Novel Botulinum Toxin in Japan.
Tokyo, Japan, October 12, 2017 — Teijin Limited announced today that it has signed an exclusive license and co-development agreement with Merz Pharma GmbH & Co. KGaA Opening a new window regarding Xeomin (incobotulinumtoxinA), the novel type A botulinum neurotoxin, covering all expected indications for ethical pharmaceutical use in Japan.
Xeomin (incobotulinumtoxinA) has been approved since 2005 in Europe and launched in more than 50 countries worldwide, including the United States. Today, Xeomin (incobotulinumtoxinA) is being prescribed in the EU and US to treat patients with upper limb spasticity, cervical dystonia and blepharospasm.